China Biotech Outbound Licensing Tracker 2026: The Deals Behind a New Record

2026 China Out-Licensing Deal Log

Licences from companies domiciled in mainland China or Hong Kong granting rights outside Greater China, announced in 2026 with a disclosed total of $1 billion or more or an upfront of $100 million or more — 38 deals so far, newest first. Each entry was checked against the linked announcement or report.

Buyer ← Chinese licensor. Stage is the lead asset’s stage at signing. “Up to” values include milestones that may never be paid. Verified through 19 Oct 2026.

2026 Market Data: How Each Source Counts

Several organizations publish China licensing totals, and they count differently: some include inbound deals, some only outbound, and all include milestones in headline value. The table names each source and does not mix them. Whichever series you use, 2026 is a record year.

For 2025, PharmCube’s total was first reported at $135.7 billion across 157 deals (Caixin, January 2026) and has since been revised to $138.8 billion as more terms were disclosed.

Largest Deals by Value and Upfront

Headline value and cash at signing tell different stories. The biggest headline deals are multi-program portfolios, while the biggest upfronts are spread across portfolios, clinical and approved assets, and even preclinical programs such as SciBrunch’s KRAS G12D inhibitor.

Therapeutic Areas and Modalities

Oncology still dominates China’s outbound deals, but the mix is broadening. Across the 38 deals in our log: oncology 16, immunology 7, obesity & metabolic 5, platform / multi-area 5, neuroscience 2, cardiorenal 2, respiratory 1.

• Antibody–drug conjugates: Hansoh’s portfolio deal with Roche, MediLink’s B7-H3 ADC (also to Roche), Alphamab’s TROP2×HER3 bispecific ADC and DualityBio’s new-payload platform. See our ADC market guide.
• T-cell engagers: increasingly for autoimmune disease — Antengene (UCB), METiS (Boulevard Bio), Abogen (Novartis) — alongside Zelgen’s DLL3 trispecific (AbbVie) and Simcere’s B-cell trispecific (Roche).
• RNA medicines: siRNA deals from Ribo (Madrigal), Frontier and SiranBio (GSK), CSPC (AstraZeneca) and Rona (Roche), plus Abogen’s mRNA-encoded engager.
• Obesity: CSPC’s eight-program deal with AstraZeneca and Hengrui’s oral GLP-1/GIP agonist for Novo Nordisk.
• Targeted small molecules: SciBrunch’s KRAS G12D inhibitor (Merck, $400 million upfront), Genhouse’s MAT2A inhibitor (Gilead) and Dizal’s approved EGFR inhibitor (AstraZeneca, $600 million upfront).

Most Active Buyers and Licensors

Innovent licensed programs to Lilly, Pfizer and Spero; Haisco to Lilly, Nuvectis and the NewCo Sentivera. Hengrui’s deals with Bristol Myers Squibb and Novo Nordisk followed its 2025 portfolio agreement with GSK. For profiles of these companies, see top Chinese biotech companies.

Deal Structures and Stage at Signing

Most China-origin assets are licensed early, and most of the value is contingent. Upfront cash averaged 5.9% of headline value across the deals in our log that disclosed both figures, in line with the 5.8% VBInsight reports for the first half of 2026.

Negotiating these terms is the subject of our cross-border term sheet guide.

The NewCo Licensing Model

Instead of licensing to an established pharma company, a Chinese licensor grants ex-China rights to a newly formed, investor-backed company and takes equity alongside cash. The licensor keeps upside if the NewCo raises capital, lists or is acquired; the investors get a de-risked asset with a defined development plan.

• Harbour BioMed → Solstice Oncology (Feb 2026): porustobart, an anti-CTLA-4 antibody, for $55 million in cash plus more than $50 million in Solstice equity and up to about $1.1 billion in milestones. In September 2026 Solstice announced a $225 million Series A led by RA Capital.
• METiS TechBio → Boulevard Bio (Jun 2026): a trispecific T-cell engager for $20 million upfront and up to $1.6 billion in milestones.
• Haisco → Sentivera (Aug 2026): a preclinical type 2 inflammation program to a new US company founded by ARCH Venture Partners and Population Health Partners, for about $76 million in cash and equity.

Structuring a NewCo is one of our NewCo formation services.

BIOSECURE and Manufacturing

The BIOSECURE Act debate targets biotechnology companies of concern and the manufacturing, genomics and services relationships around them. It does not prohibit licensing a drug candidate from a Chinese company, and 2026 deal volumes show buyers have not stopped doing so.

Due Diligence Framework for Chinese Assets

Evaluating China-originated assets needs the usual scientific and commercial diligence plus a few cross-border checks. Our pharma due diligence checklist covers the full process; these are the China-specific items.

1. Data integrity and clinical quality: review site monitoring, GCP compliance and whether Chinese trial designs and comparators support FDA and EMA filings, or need bridging studies.
2. IP and freedom to operate: confirm composition of matter, sequence and process patents in the buyer’s markets, not only in China.
3. Manufacturing and CMC: test whether the process, analytics and stability data transfer to a non-Chinese manufacturer — the most common gap.
4. Regulatory path: map the NMPA data package against FDA and EMA requirements; see our NMPA approval guide.
5. Governance: agree joint committees, decision rights and data-sharing terms before signing, especially where the licensor keeps Greater China.

Conclusion

2026 has confirmed China as the largest external source of licensable drug candidates for global pharma. The deals are bigger, the buyers are the industry’s largest companies, and the assets are mostly early, which keeps upfront cash a small share of headline value. For licensors, the choice of structure — portfolio, option, NewCo or straight licence — now matters as much as the asset. Our out-licensing and in-licensing teams work on both sides of these transactions.

Frequently Asked Questions

Methodology & Sources

The deal log includes licensing, collaboration and option deals announced between 1 January and 19 Oct2026 in which a company domiciled in mainland China or Hong Kong grants rights outside Greater China, with a disclosed total of $1 billion or more or an upfront of $100 million or more. Terms are as disclosed; “upfront & near-term” means the announcement combined the two. Stage is the lead asset’s stage at signing as described in the announcement. Each deal was checked against the linked source. Market totals come from the providers named in the market data table and are not combined.

Sources:

1. Vision Lifesciences research: our own deal tracking and insights from our day-to-day cross-border licensing and M&A advisory work (about us)
2. Reuters Breakingviews, China biotech’s ingenuity extends to dealmaking (16 Oct 2026; PharmCube data)
3. The Standard, China innovative drug out-licensing deal value reaches new high in H1 2026 (CCTV, NMPA data)
4. South China Morning Post, China biotech deals hit record in Q1 2026 (NMPA data)
5. Xinhua / gov.cn, Value of China’s innovative drug out-licensing deals hit new high in H1 (MIIT, 20 Jul 2026)
6. VCBeat, 2026 H1 Licensing Landscape (VBInsight data)
7. J.P. Morgan, Q3 2026 Biopharma Licensing and Venture Report (DealForma data)
8. Caixin Global, Chinese drugmakers strike record $136 billion in cross-border licensing deals (Jan 2026; PharmCube data)
9. BioSpace, Hengrui licenses heart disease drug to US startup Braveheart Bio (Sep 2025)
10. BioCentury, With deep pockets, Solstice takes next-gen CTLA-4 into neoadjuvant treatment (Sep 2026)